JPS63126830A - Method for forming antibody in body of animal and plant - Google Patents
Method for forming antibody in body of animal and plantInfo
- Publication number
- JPS63126830A JPS63126830A JP27358086A JP27358086A JPS63126830A JP S63126830 A JPS63126830 A JP S63126830A JP 27358086 A JP27358086 A JP 27358086A JP 27358086 A JP27358086 A JP 27358086A JP S63126830 A JPS63126830 A JP S63126830A
- Authority
- JP
- Japan
- Prior art keywords
- animal
- magnesium chloride
- plant
- inoculated
- orally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 60
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 30
- 229960005486 vaccine Drugs 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 244000052769 pathogen Species 0.000 claims abstract description 10
- 230000002238 attenuated effect Effects 0.000 claims abstract description 3
- 230000037396 body weight Effects 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 244000309466 calf Species 0.000 abstract description 24
- 241000283690 Bos taurus Species 0.000 abstract description 21
- 241000894006 Bacteria Species 0.000 abstract description 10
- 230000001717 pathogenic effect Effects 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000003211 malignant effect Effects 0.000 abstract description 3
- 241000700605 Viruses Species 0.000 abstract description 2
- 230000009385 viral infection Effects 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 description 13
- 208000030270 breast disease Diseases 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 210000002445 nipple Anatomy 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000000249 desinfective effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000010359 Newcastle Disease Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
【発明の詳細な説明】
ｒ産業上の利用分野１
本発明は、動植物主として牛に塩化マグネシウムを所定
量接種又は経口投与することにより１体内に各種ウィル
スの抗体を生成するとともに、各種菌のバランスを保つ
ことにより、成牛、仔牛等のＵ康管理と、ウィルス感染
を極力少なくして悪性病気の予防とともに、仔牛の成育
促進、牛乳搾取縫の拡大等を図ることを目的とする動植
物の体内に抗体を生成する方法に関するものである。Detailed Description of the Invention r Industrial Field of Application 1 The present invention produces antibodies against various viruses in the body by inoculating or orally administering a predetermined amount of magnesium chloride to animals and plants, mainly cattle, and improves the balance of various bacteria. The aim is to manage the health of adult cows and calves, prevent malignant diseases by minimizing virus infections, promote the growth of calves, and expand milk exploitation by maintaining the internal health of animals and plants. The present invention relates to a method for producing antibodies.
ｒ従来の技術１
周知の如く動植物の体内に抗体が生成されれば、感染過
程とかアレルギー過程から動植物を守り得るものであり
、抗原物質を注意深く使用していくことによって、任意
に免疫とか、抵抗体を導くことができる。これは通常ワ
クチンとか、アレルギー物質とか、これらに類似するも
のを使用することによってなされている。そうして本発
明の塩化マグネシウムを利用して抗体を生成する方性と
はその目的を異にするが、塩化マグ、ネシウムを疾病の
治癒、予防に使用する方法がある０例えば技術文献では
、特公昭５１−５０４５号で動物ワクチンがある。これ
は養鶏のニューカッスル病の生ワクチン及び養鶏の伝染
性コリーザの不活化ワクチンを含有する混合ワクチンで
、ニューカッスル病等の呼吸器系の養鶏の疾病を防止し
て致死率を下げ得る免疫効果が大いに期待できる処が特
徴である。また特公昭５５−２５１６では、牛の尿石症
の治療及び予防方法がある。これは各種のマグネシウム
塩を牛にマグネシウムに換して０．００２〜ｏ、００６
ｇ／ＩＫｇ体重９日経ロ投与する方法で１通常濃ｎ飼料
の過給と粗飼料の不足に起因する前記の疾病を治療及び
予防に役立つものとされている。更には特公昭５９−２
９２１０号では置市用マグネシウム固形塩があり、これ
は食塩にミネラル類、その他愛養剤の配合物と酸化マグ
ネシウム及びこの酸化マグネシウムと反応して複塩を形
成する特定の物質を混合して構成するもので、グラステ
タニ一様疾患を防止、治癒することにある。rPrior art 1 As is well known, if antibodies are produced in the body of an animal or plant, it can protect the animal or plant from infectious or allergic processes, and by carefully using antigenic substances, it is possible to arbitrarily develop immunity or resistance. You can guide your body. This is usually done through the use of vaccines, allergens, and the like. Although the purpose is different from the method of producing antibodies using magnesium chloride of the present invention, there is a method of using magnesium chloride and nesium for curing and preventing diseases. For example, in technical literature, There is an animal vaccine in Special Publication No. 51-5045. This is a combination vaccine containing a live chicken Newcastle disease vaccine and an inactivated poultry infectious coryza vaccine, and it has a great immune effect that can prevent respiratory diseases such as Newcastle disease and reduce the mortality rate. It is characterized by a place that can be expected. Furthermore, Japanese Patent Publication No. 55-2516 describes a method for treating and preventing urolithiasis in cattle. This is 0.002 to 0.006 by converting various magnesium salts into magnesium for cows.
It is said that the method of administering g/Ikg body weight every 9 days is useful for treating and preventing the above-mentioned diseases caused by overfeeding of concentrated feed and lack of forage. Furthermore, special public service 59-2
In No. 9210, there is a magnesium solid salt for use in Okiichi, which is made by mixing common salt, minerals, a combination of other nourishing agents, magnesium oxide, and a specific substance that reacts with this magnesium oxide to form a double salt. The aim is to prevent and cure Grass Tetani-like diseases.
ｒ発明が解決しようとする問題点」
前述の如く確かにワクチンの使用によって抗体が生成さ
れ、それなりの成果は期待できるがその反面天然抗原の
不十分な不活性化により接種動植物に不所望な副作用が
生じるとともに、この不活性化により天然抗原がある程
度変えられ、損失する虞れがあるし、また本来必要とす
る菌類をも死滅させ、体内の菌＼のバランスを崩すおそ
れが多分にあφものと思われること、更に前述の各技術
文献は塩化マグネシウムの特異性を中に一面的に捉え、
これを疾病の治療、予防等に利用しているにすぎす、本
発明が目的とする抗体の生成とか、主として牛の疾病防
止、Ｉ＆育環境の向上等とは到底期待できないものであ
ります。``Problems to be Solved by the Invention'' As mentioned above, it is true that antibodies are produced through the use of vaccines and certain results can be expected, but on the other hand, undesirable side effects may occur in the inoculated animals and plants due to insufficient inactivation of natural antigens. As well as this inactivation, there is a possibility that natural antigens may be altered to some extent and lost, and there is also a risk that the fungi that are originally needed may be killed and the balance of bacteria in the body may be disrupted. What seems to be the case, and furthermore, each of the above-mentioned technical documents takes a one-dimensional view of the specificity of magnesium chloride,
If this is used for the treatment or prevention of diseases, it cannot be expected to produce antibodies, which is the purpose of the present invention, mainly to prevent diseases in cattle, and to improve the breeding environment.
ｒ問題点を解決するための手段１
上記に鑑み、本発明は、動植物主として牛が病原体に対
して感受性をもたないか、或いは感受性が減弱された状
態にあるようにするために、動植物に不活性な病原体を
含有するいわゆる死菌ワクチン又は弱毒性病原体を含有
するいわゆる生菌ワクチンを接種又は経口投与して発病
又は感染させた後、塩化マグネシウムの所定量を接種又
は経口投与することにより動植物の体内に抗体を生成す
る方法を提供することにある。Means for Solving Problems 1 In view of the above, the present invention provides methods for treating animals and plants, mainly cattle, so that they are not susceptible to pathogens or have reduced susceptibility to pathogens. After inoculating or orally administering a so-called killed vaccine containing an inactive pathogen or a so-called live vaccine containing a weakened pathogen to cause disease or infection, animals and plants can be infected by inoculating or orally administering a predetermined amount of magnesium chloride. The objective is to provide a method for producing antibodies in the body of a patient.
１作用」 次に本発明の作用いわゆる実験例を説明する。1 action” Next, a so-called experimental example of the operation of the present invention will be explained.
（Ｉ）乳房症の防止について、
搾乳する前に塩化マグネシウムの０．３水溶液を乳房及
び／又は乳頭を消毒すると乳房症に極めてかかりにくい
。(I) Regarding the prevention of mastopathy, if the breast and/or teat are disinfected with a 0.3 aqueous solution of magnesium chloride before milking, the risk of mastopathy is extremely low.
これは、牛乳が牛の体内及び乳房を介して無菌の状態で
生成されるために、乳酸菌とかその他一般の雑菌が外部
から乳頭を介して侵入する。これによって乳房症にかか
ると思われる。そこで、塩化マグネシウムで乳房及び／
又は乳頭を消毒することによって、この時点で毒性の強
くかつ媒介の早い雑菌を死滅させ得るし、また塩化マグ
ネシウムで乳房及び／又は乳頭を消毒することは菌類の
バランスを保つことになると思われるため前記の乳房症
にはかからないものである。This is because milk is produced in a sterile state through the cow's body and udder, so lactic acid bacteria and other common bacteria can invade from the outside through the teat. This is thought to cause mastopathy. Therefore, magnesium chloride was applied to the breast and/or
Alternatively, by disinfecting the teats, highly toxic and fast-transmitting germs can be killed at this point, and disinfecting the breasts and/or teats with magnesium chloride seems to maintain the fungal balance. It does not suffer from the mastopathy mentioned above.
（ＩＩ）仔牛に塩化マグネシウムを接種又は経口投与し
た成牛より搾取した牛乳を飲ませることによる抗体の生
成について。(II) Regarding the production of antibodies by allowing calves to drink milk extracted from adult cows that have been inoculated or orally administered with magnesium chloride.
仔牛の体内に塩化マグネシウムをＯ，００１ｇ／１Ｋｇ
体重９日当り接種又は経口投与になると、仔牛は下痢症
状を呈しその後死滅する。O,001g/1Kg of magnesium chloride in the calf's body
When inoculated or orally administered per 9 days of body weight, calves develop diarrhea symptoms and subsequently die.
しかし、成牛の体内に塩化マグネシウムを５０ｇ／１Ｋ
ｇ体玉９日当り接種又は経「１投与して、この成牛から
搾取されｌた牛乳を仔牛に飲ませるそれ以後、原則とし
て同一条件にある仔牛の体内に仔牛の体内に塩化マグネ
シウムを０．００１ｇ／ Ｉ Ｋ ｇ体重９日当り接種
又は経口没年しても、下痢症状を呈することがないとと
もに、逆に仔牛の体内にも強い抗体が生成されると思わ
れる。However, the amount of magnesium chloride in the body of an adult cow is 50g/1K.
The calf is inoculated or given once per 9 days, and the calf is allowed to drink the milk extracted from this adult cow.Thereafter, as a general rule, administer 0.0 mg of magnesium chloride into the calf's body under the same conditions. Even if calves are inoculated at a dose of 001 g/I Kg body weight per 9 days or given orally, they will not exhibit diarrheal symptoms, and on the contrary, it is thought that strong antibodies will be produced in the calf's body.
したがって、仔牛は風邪に感染することが少なくなるし
、その他の疾病にも極めてかかりに（くなるものである
。Therefore, calves are less susceptible to colds and are much less susceptible to other diseases.
ｒ実施例１
次に本発明の一実施例を説明すると、動植物に不活性な
病原体を含有するいわゆる死菌ワクチン又は弱毒性病原
体を含有するいわゆる生菌ワクチンを接種又は経口投与
して発病又は感染させた後、塩化マグネシウムの所定量
を接種又は経口投与する。この場合塩化マグネシウムの
接種又は経口投与は、塩化マグネシウムが動植物に含有
する水分に対して、その水分に溶ける範囲内とするが。r Example 1 Next, an example of the present invention will be described. Animals and plants are inoculated or orally administered with a so-called killed vaccine containing an inactive pathogen or a so-called live vaccine containing an attenuated pathogen to cause disease or infection. After this, a predetermined amount of magnesium chloride is inoculated or orally administered. In this case, inoculation or oral administration of magnesium chloride should be within the range in which magnesium chloride is soluble in the water contained in animals and plants.
その範囲内であるかぎり塩化マグネシウムの所定量が増
えばそれだけ強い抗体が生成されるものと思われる。具
体的には動物中例えば成牛に含有する水分が７５％との
場合は、塩化マグネシウムは５０％は溶けるので略０．
０３〜４００ｇ／ＩＫｇ体重９日を最大とする。尚体内
の塩化マグネシウムは例えば尿等とともに排潰されるの
で何ら障害とはならないものである。As long as the predetermined amount of magnesium chloride increases, as long as it is within this range, it is believed that stronger antibodies will be produced. Specifically, if the water content of an animal, such as an adult cow, is 75%, 50% of magnesium chloride is soluble, so the water content is approximately 0.
03-400g/IKg body weight 9 days is the maximum. Magnesium chloride in the body is excreted together with urine, for example, so it does not pose any problem.
そこで以下本発明の実験例を詳細に説明する。Therefore, experimental examples of the present invention will be explained in detail below.
（Ｉ）乳房症の防止について、
搾乳する前に塩化マグネシウムの０．３水溶液を乳房及
び／又は乳頭を消毒すると乳房症に極めてかかりにくい
。(I) Regarding the prevention of mastopathy, if the breast and/or teat are disinfected with a 0.3 aqueous solution of magnesium chloride before milking, the risk of mastopathy is extremely low.
これは、牛乳が牛の体内及び乳房を介して無菌の状態で
生成されるために、乳酸菌とかその他一般の雑菌が外部
から乳頭を介して侵入する。これによって乳房症にかか
ると思われる。そこで、塩化マグネシウムで乳房及び／
又は乳頭を消毒することによって、この時点で毒性の強
くかつ媒介の瞥Ｎい３１菌（主として水を媒介として作
用する雑菌）を死滅させ得るし、また塩化マグネシウム
で乳ＤＩ及び／又は乳頭を消みすることは菌類のバラン
スを保つことになると思われるため前記の乳房症にはか
からないものである。よって、従来の抗生物質による治
療では、不可能とされていた悪性の乳房症から良性の乳
房症まで略完全に治癒又は予防することができると思わ
れる。This is because milk is produced in a sterile state through the cow's body and udder, so lactic acid bacteria and other common bacteria can invade from the outside through the teat. This is thought to cause mastopathy. Therefore, magnesium chloride was applied to the breast and/or
Alternatively, by disinfecting the teats, highly toxic and vector-borne bacteria (bacteria that act primarily through water) can be killed at this point, and milk DI and/or teats can be sterilized with magnesium chloride. This is thought to help maintain the balance of fungi, so it does not cause the aforementioned mastopathy. Therefore, it seems possible to almost completely cure or prevent both malignant and benign mastopathy, which was considered impossible with conventional antibiotic treatment.
（ＩＩ）仔牛に塩化マグネシウムを接種又は経口投ｒし
た成牛より搾取した牛乳を飲ませることによる抗体の生
成について、
仔牛の体内に塩化マグネシウムを０．００１ｇ／ＩＫｇ
体重２日当り接種又は経口投与になると、仔牛は下痢症
状を呈しその後死滅する。(II) Regarding the production of antibodies by inoculating or orally administering magnesium chloride to calves and allowing them to drink milk extracted from adult cows, administering 0.001g/IKg of magnesium chloride into the body of the calf.
When inoculated or orally administered per 2 days of body weight, calves develop diarrhea symptoms and subsequently die.
しかし５成牛の体内に塩化マグネシウムを５０ｇ／ＩＫ
ｇ体重９口当り接種又は経口役テして、この成牛から搾
取された牛乳を仔牛に飲ませる。However, 50g/IK of magnesium chloride was added to the body of an adult cow.
The milk extracted from this adult cow is given to the calf by inoculation or oral administration per 9 g of body weight.
それ以後、原則として同一条件にある仔牛の体内に仔牛
の体内に塩化マグネシウムをｏ、ｏｏｔｇ／ＩＫｇ体重
１日ちり接種又は経口投与しても、下痢症状を呈するこ
とがないとともに、逆に仔牛の体内にも強い抗体が生成
されると思われるのである。Since then, as a general rule, even if magnesium chloride is inoculated or orally administered to calves under the same conditions, o, ootg/IKg body weight per day, they do not exhibit diarrheal symptoms, and conversely, calves do not develop diarrhea symptoms. It is thought that strong antibodies are produced in the body as well.
したがって、仔牛は風邪に感染することが少なくなる。Therefore, calves are less susceptible to cold infections.
またその他の疾病にも極めてかかりにくくなるものであ
る。そうして仮に仔牛が風邪をひく等の疾病になり４２
℃の熱をだしても、下痢の症状はなくしかも脱水症状を
もすさないことが判明した。It also makes them extremely less susceptible to other diseases. Then, if the calf were to catch a cold or other illness42
It has been found that even if the patient has a fever of 15°F, there are no symptoms of diarrhea or dehydration.
以上は成牛、仔牛等の牛について詳述したが、その他の
動植物についても同様に考えられる。The above description has been given in detail for cows such as adult cows and calves, but the same applies to other animals and plants.
ｒ発明の効果１
以上詳述の如く、動植物に死菌ワクチン又は生菌ワクチ
ンを接種又は経口役饗して発病又は感染させた後、動植
物の体内に所定量の塩化マグネシウムを接種又は経口投
与することにより、動植物の体内の強い抗体が生成され
る効果があり、成牛等の疾病の予防と治癒ができるし、
仔牛のｒ＆長促進と成育環境の向上に大いに寄与できる
し、更には搾乳量の拡充と品質の向上が大いに期待でき
るものである０、また体内の菌のバランスを常に維持で
きるものであり、これは成牛等の疾病の予防と治癒に、
又は仔牛の１＆長促進と成育環境の向上にとって誠に有
益なものである等の効果があり畜産業溝、農業者等にと
って誠に有意義である。r Effect of the invention 1 As detailed above, after inoculating or orally administering a killed or live vaccine to an animal or plant to cause disease or infection, a predetermined amount of magnesium chloride is inoculated or orally administered into the body of the animal or plant. This has the effect of producing strong antibodies in the bodies of animals and plants, which can prevent and cure diseases in adult cattle, etc.
It can greatly contribute to promoting the R & L length of calves and improving the growing environment, and can also be expected to greatly increase milk production and improve quality.0 It can also constantly maintain the balance of bacteria in the body. is for the prevention and cure of diseases in adult cattle, etc.
It is also very beneficial for promoting the growth of calves and improving the growing environment, and is very meaningful for the livestock industry, farmers, etc.
Claims (2)
ワクチン又は弱毒性病原体を含有するいわゆる生菌ワク
チンを接種又は経口投与して発病又は感染させた後、塩
化マグネシウムの所定量を接種又は経口投与することに
より動植物の体内に抗体を生成する方法。(1) After inoculating or orally administering so-called killed vaccines containing inactive pathogens or so-called live vaccines containing attenuated pathogens to cause disease or infection, a prescribed amount of magnesium chloride is inoculated or orally administered to animals and plants. A method of producing antibodies in the body of animals and plants by administration.
ウムの所定量が略０．０３〜４００ｇ／１Ｋｇ体重、日
である特許請求の範囲第１項記載の動植物の体内に抗体
を生成する方法。(2) The method for producing antibodies in the body of an animal or plant according to claim 1, wherein the predetermined amount of magnesium chloride inoculated or orally administered into the body of the cow is approximately 0.03 to 400 g/1Kg body weight/day. .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27358086A JPS63126830A (en) | 1986-11-17 | 1986-11-17 | Method for forming antibody in body of animal and plant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27358086A JPS63126830A (en) | 1986-11-17 | 1986-11-17 | Method for forming antibody in body of animal and plant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63126830A true JPS63126830A (en) | 1988-05-30 |
Family
ID=17529777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP27358086A Pending JPS63126830A (en) | 1986-11-17 | 1986-11-17 | Method for forming antibody in body of animal and plant |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63126830A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005516915A (en) * | 2001-12-11 | 2005-06-09 | インスティティ・パスツール | Gram-positive bacterial preparations for the treatment of diseases involving immune dysregulation |
-
1986
- 1986-11-17 JP JP27358086A patent/JPS63126830A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005516915A (en) * | 2001-12-11 | 2005-06-09 | インスティティ・パスツール | Gram-positive bacterial preparations for the treatment of diseases involving immune dysregulation |
| US7871627B2 (en) | 2001-12-11 | 2011-01-18 | Institut Pasteur | Gram positive bacteria preparations for the treatment of disease comprising an immune dysregulation |
| US8404250B2 (en) | 2001-12-11 | 2013-03-26 | Institut Pasteur | Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saltzburg | Federal Rules of Evidence Manual | |
| NO159782B (en) | SPRING SYSTEM DEVICE, FIRST AND FIRST ON VEHICLES. | |
| Pelzer et al. | Zoonotic diseases of cattle | |
| JP2001309753A (en) | Dog food for prevention and treatment of dog-specific infectious diseases | |
| Sreeparvathy et al. | Autogenous vaccination as a treatment method for bovine papillomatosis. | |
| RU2678132C2 (en) | Canine health product containing antibodies against canine parvovirus type 2 | |
| JPS63126830A (en) | Method for forming antibody in body of animal and plant | |
| JP3788689B2 (en) | Livestock health promotion methods | |
| Ploeger et al. | Production of dairy replacement stock in relation to level of exposure to gastrointestinal nematode infection in the first grazing season: second-year calves and heifers | |
| CN113845588B (en) | Preparation method and application of yolk antibody for resisting porcine rotavirus | |
| RU2202882C2 (en) | Method for double suckling raising of young animals | |
| RU2780858C1 (en) | Method for rearing piglets in farms that are disadvantaged in terms of haemophilous polyserositis | |
| NO119491B (en) | ||
| RU2014836C1 (en) | Preparation and method for treatment of acute respiratory diseases in calves | |
| Mwera et al. | Dairy animal health management/Kurinda ubuzima bw’inka z’umukamo | |
| US20150344545A1 (en) | Method of Treating and Preventing Infectious Diseases Using Colostrum | |
| Raw | Immunization of Animals and Man against Tuberculosis | |
| RU2010564C1 (en) | Method for prophylaxis/and medical treatment of acute respiratory diseases | |
| Singh | Common cattle diseases: Symptoms, treatment and prevention | |
| Bannoud | ETIOLOGY OF THE SPREAD OF FOOT AND MOUTH DISEASE AND PREVENTIVE MEASURES IN THE SYRIAN ARAB REPUBLIC | |
| CN121336760A (en) | A method for caring for and feeding donkey foals in their infancy. | |
| Hambidge | Keeping livestock healthy | |
| Bevan | A Specific Lung Disease of Calves | |
| Du Preez | Buffalo disease-deadly for cattle | |
| Monlux et al. | Actinomycosis and actinobacillosis |